Adrian Kee Keong TEO

Adjunct Assistant Professor

Affiliations

Adjunct Assistant Professor, Department of Biochemistry, Yong Loo Lin School of Medicine, NUS.
Junior Investigator, Institute of Molecular and Cell Biology, A*STAR.
Adjunct Assistant Professor, School of Biological Sciences, Nanyang Technological University.

Education

Degree and Institution Year(s)
Postdoctoral training - Joslin Diabetes Center, Harvard Medical School, Boston, USA 2011-2014
Postdoctoral training - Institute of Medical Biology, A*STAR, Singapore 2010-2011
Ph.D. - University of Cambridge, Cambridge, UK 2008-2010
B.Sc. (1st Class Honours) - National University of Singapore, Singapore 2003-2006

Professional Experience

Position and Institute Year(s)
Adjunct Assistant Professor, Department of Biochemistry, Yong Loo Lin School of Medicine, NUS 2014-Present
Junior Investigator, Institute of Molecular and Cell Biology, A*STAR, Singapore 2014-Present
Adjunct Assistant Professor, School of Biological Sciences, Nanyang Technological University, Singapore 2014-Present
Postdoctoral Fellow, Joslin Diabetes Center, Harvard Medical School, Boston, USA 2011-2014
Postdoctoral Fellow, Institute of Medical Biology, A*STAR, Singapore 2010-2011
Ph.D. Candidate, University of Cambridge, Cambridge, UK 2008-2010
Research Officer, Institute of Medical Biology, A*STAR, Singapore 2007-2008
Research Officer, ES Cell International Pte Ltd, Singapore 2007
Undergraduate, B.Sc. (1st Class Honours), National University of Singapore, Singapore 2003-2006
Research Studentship, Department of Biological Sciences, National University of Singapore, Singapore 2006
Research Studentship, Department of Anatomy, National University of Singapore, Singapore 2005
Research Internship, Institute of Bioengineering and Nanotechnology, A*STAR, Singapore 2004
Research Studentship, Department of Biological Sciences, National University of Singapore, Singapore 2004
Research Internship, Genome Institute of Singapore, A*STAR, Singapore 2004

Research Interest

Adrian TEO’s laboratory focuses on:

* Modelling and studying human pancreas development in vitro.
hPSCs will be differentiated into human pancreatic cells to study the development and formation of functionally mature β cells. This is aimed at identifying critical steps, key pathways and mechanisms which guide human β cell development and maturation. It is hoped that one would be able to produce sufficient mature functional human β cells for cell replacement therapy to achieve physiological control of blood glucose levels.

* Studying mechanisms by which genes and gene variants cause diabetes.
hiPSCs derived from patients with maturity onset diabetes of the young (MODY), a monogenic form of diabetes, will be used to study human β cell development, maturation and function. hiPSCs derived from diabetic patients with a risk allele that could potentially confer diabetes susceptibility will be differentiated into pancreatic cells to functionalise gene variants associated with diabetes. The tracking of early diabetes progression in vitro seeks to pinpoint mechanisms of β cell demise at the earliest stage(s). This is otherwise not possible given that clinical manifestation of overt diabetes in humans takes decades to occur and patient material is inaccessible.

* Studying mechanisms underlying diabetic complications.
hiPSCs derived from diabetic patients with and without complications, such as diabetic nephropathy, will be differentiated into kidney cells to elucidate genetic and epigenetic perturbations which occur in cells/tissues/organs constantly exposed to hyperglycemia.

Selected Publications

  1. Teo, K.K.A.*, Valdez, I.A., Dirice, E., and Kulkarni, R.N.* (2014). Comparable generation of Activin-induced definitive endoderm via additive Wnt or BMP signalling in absence of serum. Stem Cell Reports 3, 5-14.
    *Corresponding authors

  2. Dirice, E., Kahraman, S., Jiang, W., El Ouaamari, A., De Jesus, D., Teo, K.K.A., Hu, J., Kawamori, D., Gaglia, J., Mathis, D., and Kulkarni, R.N. (2014). Soluble factors secreted by T-cells promote β cell proliferation. Diabetes 63, 188-202.

  3. Teo, K.K.A., Wagers, A.J., and Kulkarni, R.N. (2013). New opportunities: harnessing induced pluripotency for discovery in diabetes and metabolism. Cell Metabolism 18, 1-17.

  4. Teo, K.K.A., Windmueller, R., Johansson, B.B., Dirice, E., Njolstad, P.R., Tjora, E., Raeder, H., and Kulkarni, R.N. (2013). Derivation of human induced pluripotent stem cells from patients with maturity onset diabetes of the young. J Biol Chem. 288, 5353-5356.

  5. Teo, K.K.A.*, Ali, Y.*, Wong, K.Y., Chipperfield, H., Sadasivam, A., Poobalan, Y., Tan, E.-K., Wang, S.-T., Abraham, S., Tsuneyoshi, N., Stanton, L.W., and Dunn, N.R. (2012). Activin and BMP4 synergistically promote formation of definitive endoderm in human embryonic stem cells. Stem Cells 30, 631-642.
    *Equal contribution

  6. Brown, S., Teo, K.K.A., Pauklin, S., Hannan, N., Cho, C.H.-H., Lim, B., Vardy, L., Dunn, N.R., Trotter, M.W.B., Pedersen, R., and Vallier, L. (2011). Activin/Nodal signalling controls divergent transcriptional networks in human embryonic stem cells and in endoderm progenitors. Stem Cells 29, 1176-1185.

  7. Teo, K.K.A., Arnold, S.J., Trotter, M.W.B., Brown, S., Ang, L.T., Chng, Z., Robertson, E.J., Dunn, N.R., and Vallier, L. (2011). Pluripotency factors regulate definitive endoderm specification through Eomesodermin. Genes Dev. 25, 238-250.

  8. Teo, K.K.A., and Vallier, L. (2010). Emerging use of stem cells in regenerative medicine. Biochem. J. 428, 11-23.

  9. Chng, Z., Teo, K.K.A., Pedersen, R.A., and Vallier, L. (2010). SIP1 mediates cell-fate decisions between neuroectoderm and mesendoderm in human pluripotent stem cells. Cell Stem Cell 6, 59-70.

  10. Vallier, L., Mendjan, S., Brown, S., Chng, Z., Teo, K.K.A., Smithers, L.E., Trotter, M.W., Cho, C.H., Martinez, A., Rugg-Gunn, P., Brons, G., and Pedersen, R.A. (2009). Activin/Nodal signalling maintains pluripotency by controlling Nanog expression. Development 136, 1339-1349